Featured Research

from universities, journals, and other organizations

New definition of kidney disease for clinical trials could lead to new treatments

Date:
June 3, 2014
Source:
Johns Hopkins University Bloomberg School of Public Health
Summary:
New therapies for kidney disease could be developed more quickly by revising the definition of kidney disease progression used during clinical trials, experts say. If adopted, the new definition could shorten the length of some clinical trials and also potentially encourage more clinical trials in kidney disease.

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that new therapies for kidney disease could be developed more quickly by revising the definition of kidney disease progression used during clinical trials. If adopted, the new definition could shorten the length of some clinical trials and also potentially encourage more clinical trials in kidney disease. The findings will be published in the June 3, 2014 online edition of the Journal of the American Medical Association.

Chronic kidney disease (CKD) is a worldwide public health problem that affects 26 million Americans in the U.S., with 600,000 requiring dialysis or kidney transplantation. Despite its prevalence, there are fewer clinical trials for kidney disease than any other common disease. In December 2012, the National Kidney Foundation (NKF) and the Food and Drug Administration (FDA), challenged the research community to evaluate the current definition of kidney disease progression and examine whether improvements were possible. At that time, NFK and FDA officials viewed favorably emerging evidence that a decline in estimated kidney function was promising as a reliable indicator of kidney disease progression. This research grew directly out of the NFK-FDA challenge.

For the study, a global Chronic Kidney Disease Prognosis Consortium led by Josef Coresh, MD, PhD, MHS, a professor at the Bloomberg School, analyzed data from 1.7 million participants recruited into 35 cohorts in dozens of countries from 1975-2011 and followed for an average of 5 years. The researchers' points of comparison were the FDA's current definition of CKD disease onset for clinical trials -- a doubling of serum creatinine, a blood marker that assesses kidney function -- and the emerging evidence on a decline in estimated kidney function.

Researchers first analyzed kidney disease progression among all participants during a baseline period of two years. They then examined how this progression predicted subsequent disease progression to the observed 12,344 cases of end-stage renal diseases (ESRD) and 223,944 deaths. The study found that the current serum-creatinine standard used in clinical trials which is associated with a 57% reduction in kidney function carried very high risk -- a 32-fold increased risk of ESRD and 3.7-fold increased risk of mortality but only occurred in less than 1% of participants in the two-year baseline period.

In contrast, a 30% decline in kidney function, also measured by serum creatinine levels, occurred in 7% of participants in the two-year baseline period. This was associated with a 5-fold higher risk of end-stage renal disease (ESRD) and 1.8-fold higher risk of mortality. This level of risk is high and yet common and early enough to facilitate testing if new therapies are working.

"Chronic kidney disease is often asymptomatic until it's too late," notes Dr. Coresh. "This new definition will help standardize following patients to determine when their disease progresses significantly enough to elevate risk. This will assist in patient care, research studies and development of new therapies."


Story Source:

The above story is based on materials provided by Johns Hopkins University Bloomberg School of Public Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Josef Coresh, Tanvir Chowdhury Turin, Kunihiro Matsushita, Yingying Sang, Shoshana H. Ballew, Lawrence J. Appel, Hisatomi Arima, Steven J. Chadban, Massimo Cirillo, Ognjenka Djurdjev, Jamie A. Green, Gunnar H. Heine, Lesley A. Inker, Fujiko Irie, Areef Ishani, Joachim H. Ix, Csaba P. Kovesdy, Angharad Marks, Takayoshi Ohkubo, Varda Shalev, Anoop Shankar, Chi Pang Wen, Paul E. de Jong, Kunitoshi Iseki, Benedicte Stengel, Ron T. Gansevoort, Andrew S. Levey. Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. JAMA, 2014; DOI: 10.1001/jama.2014.6634

Cite This Page:

Johns Hopkins University Bloomberg School of Public Health. "New definition of kidney disease for clinical trials could lead to new treatments." ScienceDaily. ScienceDaily, 3 June 2014. <www.sciencedaily.com/releases/2014/06/140603182559.htm>.
Johns Hopkins University Bloomberg School of Public Health. (2014, June 3). New definition of kidney disease for clinical trials could lead to new treatments. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2014/06/140603182559.htm
Johns Hopkins University Bloomberg School of Public Health. "New definition of kidney disease for clinical trials could lead to new treatments." ScienceDaily. www.sciencedaily.com/releases/2014/06/140603182559.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins